American psychiatrist Karl Deisseroth alongside German researchers Peter Hegemann and Georg Nagel have been awarded the Nobel Prize in Physiology or Medicine for pioneering optogenetics. The Nobel Assembly at Sweden`s Karolinska Institute announced the honor on Monday, praising the laureates for revolutionising scientific comprehension of the human brain. Their research established techniques allowing scientists to control cellular electrical signals using light, according to Reuters and the Nobel Committee.
The discovery inaugurated a transformative era across experimental neuroscience.
The Nobel Committee highlighted that the laureates laid the foundations for manipulating specific neural circuits responsible for memories, moods, and complex behaviours. By isolating mechanisms underlying psychiatric conditions, the research resolved foundational dilemmas regarding neurological functions. The laureates will split a financial award of 12 million Swedish kronor, equivalent to approximately 900,000 pounds. In a shared statement, the scientists termed the recognition absolutely wonderful, describing it as an immense honor to celebrate the milestone alongside professional collaborators.
Per Svenningsson, chair of the Nobel Committee, explained that optogenetics facilitated brain mapping at resolutions previously deemed unreachable. The process relies on light-sensitive proteins derived from microscopic algae to regulate the electrical impulses of selected cells. In the early 2000s, Hegemann and Nagel isolated channelrhodopsin, an algal protein exhibiting unprecedented photo-receptive capabilities. Subsequently, Deisseroth developed an experimental framework deploying this molecule into the brains of laboratory mice, enabling targeted illumination to activate specific neural pathways.
The approach has expanded scientific insights beyond laboratory models into complex biological interactions. Researchers can now selectively stimulate individual neurons to analyze physiological pathways connected to neurodegenerative conditions and behavioral anomalies. The methodology has additionally revealed critical operational links between the central nervous system and distant peripheral organs, including the cardiac muscle and gastrointestinal tract.
Medical teams have commenced initial clinical applications utilizing optogenetics to treat chronic visual impairments. Ongoing clinical trials focus on patients blinded by retinitis pigmentosa, a degenerative ocular condition that destroys photoreceptor rods and cones. By delivering therapeutic algal proteins into the damaged retina and fitting patients with specialised light-emitting glasses, clinicians have successfully activated dormant nerve pathways to restore functional visual perception.
